# Anti-Inflammatory Potential of Beesioside O: Target Prediction, Docking Studies, and Molecular Dynamics

**Authors:** Qian Qiang, Qiong-Yu Zou, Lei Jin, Zheng Hu, Zi-Xuan Zhao, Hai-Feng Wu, Ji Zhang

PMC · DOI: 10.3390/cimb48020129 · 2026-01-23

## TL;DR

This study explores how Beesioside O, a natural compound, may reduce inflammation by examining its effects on cells and using computational methods.

## Contribution

The study reveals new anti-inflammatory mechanisms of Beesioside O and proposes its potential as a therapeutic agent.

## Key findings

- Beesioside O inhibits the expression of iNOS and COX-2 mRNA in macrophages.
- It regulates ERK phosphorylation, suggesting involvement in anti-inflammatory signaling.
- Molecular simulations and derivative testing support its structural and functional potential.

## Abstract

Triterpenoids with diverse structural features have shown considerable potential as pharmaceutical precursors for anti-inflammatory therapies. Beesioside O (BO), a representative triterpenoid (cycloartane triterpene saponin), has previously been reported to exhibit notable anti-HIV and anticancer activities. However, its anti-inflammatory mechanisms have not been fully elucidated. In this study, we investigated the anti-inflammatory activity and underlying molecular mechanisms of BO in LPS-induced RAW264.7 macrophages. In addition, NP AI Engine predictions, molecular docking, density functional theory (DFT) calculations, and molecular dynamics simulations were conducted to characterize the anti-inflammatory properties of BO further. The experimental results indicated that BO inhibited the mRNA expression levels of iNOS and COX-2. Moreover, it can regulate the phosphorylation of ERK at 3 h. Potential signaling pathways and targets were subsequently analyzed. The structural and electronic properties of BO were calculated using the B3LYP/6-311+G (d,p) basis set. The BO–ERK2 kinase complex was also constructed for simulation. Furthermore, a BO derivative was prepared through hydrolysis followed by acylation, and its anti-inflammatory activity was evaluated. Overall, this study provides deeper insight into the anti-inflammatory effects of BO and supports its potential for further development as an anti-inflammatory agent.

## Linked entities

- **Genes:** NOS2 (nitric oxide synthase 2) [NCBI Gene 4843], COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513], EPHB2 (EPH receptor B2) [NCBI Gene 2048]
- **Chemicals:** Beesioside O (PubChem CID 146000859)

## Full-text entities

- **Genes:** Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, Nos2 (nitric oxide synthase 2, inducible) [NCBI Gene 18126] {aka MAC-NOS, NOS-II, Nos-2, Nos2a, i-NOS, iNOS}, Mapk1 (mitogen-activated protein kinase 1) [NCBI Gene 26413] {aka 9030612K14Rik, ERK, Erk2, MAPK2, PRKM2, Prkm1}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, NOS2 (nitric oxide synthase 2) [NCBI Gene 4843] {aka HEP-NOS, INOS, NOS, NOS2A}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 17709], Blnk (B cell linker) [NCBI Gene 17060] {aka BASH, Bca, Ly-57, Ly57, Lyw-57, SLP-65}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, Il17a (interleukin 17A) [NCBI Gene 16171] {aka Ctla-8, Ctla8, IL-17, IL-17A, Il17}, Mapk14 (mitogen-activated protein kinase 14) [NCBI Gene 26416] {aka CSBP2, Crk1, Csbp1, Mxi2, PRKM14, PRKM15}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Mapk8 (mitogen-activated protein kinase 8) [NCBI Gene 26419] {aka JNK, JNK1, Prkm8, SAPK1}
- **Diseases:** tissue injury (MESH:D017695), stomatitis (MESH:D013280), infection (MESH:D007239), atherosclerosis (MESH:D050197), pharyngitis (MESH:D010612), rheumatoid arthritis (MESH:D001172), BO (MESH:C535508), metabolic syndromes (MESH:D024821), neurodegenerative disorders (MESH:D019636), injury to (MESH:D014947), Inflammation (MESH:D007249)
- **Chemicals:** H2SO4 (MESH:C033158), saponin (MESH:D012503), PVDF (MESH:C024865), H (MESH:D006859), agarose (MESH:D012685), LPS (MESH:D008070), CO2 (MESH:D002245), cycloartane (MESH:C085352), Triterpenoids (MESH:D014315), MTT (MESH:C070243), MgSO4 (MESH:D008278), pyridine (MESH:C023666), NO (MESH:D009614), 15-COCH3 (-), 13C (MESH:C000615229), EtOH (MESH:D000431), Nitric Oxide (MESH:D009569), brine (MESH:C017082), SDS (MESH:D012967), aglycone (MESH:C458179), HCl (MESH:D006851), TRIzol (MESH:C411644), TBS (MESH:D013725), BO (MESH:C486138), H2O (MESH:D014867), C (MESH:D002244), ACN (MESH:C032159), oxygen (MESH:D010100), formazan (MESH:D005562), formic acid (MESH:C030544), 3H (MESH:D014316), Methanol (MESH:D000432), H3- (MESH:C012616), Silica Gel (MESH:D058428)
- **Species:** Homo sapiens (human, species) [taxon 9606], Actaea vaginata (species) [taxon 64047], Human immunodeficiency virus 1 (no rank) [taxon 11676], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** RAW264.7 — Mus musculus (Mouse), Mouse leukemia, Cancer cell line (CVCL_0493), ATCC TIB-71 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12939579/full.md

---
Source: https://tomesphere.com/paper/PMC12939579